NATICK, Mass., May 30, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, invites investors and the general public to listen to a webcast of its Investor & Analyst Briefing on Monday, June 2 at 6:15 PM Central Time. At this briefing, Karyopharm's management team will provide a clinical update in conjunction with the 2014 American Society of Clinical Oncology (ASCO) annual meeting.
A live webcast of the Investor & Analyst Briefing can be accessed by visiting the Investors section of Karyopharm's website at www.karyopharm.com or at http://www.media-server.com/m/p/gu57npz2. The webcast of this event will be available on our website for at least 30 days.
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitors of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). The inhibition of XPO1 by Karyopharm's lead drug candidate, Selinexor (KPT-330), a first-in-class, oral SINE compound, leads to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor suppressor function. This is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. SINE compounds have shown biological activity in models of cancer, autoimmune disease, certain viruses, and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Natick, Massachusetts. For more information, please visit www.karyopharm.com.
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include the timing of the release of information regarding Karyopharm's reported earnings and development program. Any forward-looking statements contained in this press release speak only as of the date hereof, and Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Paul Brannelly firstname.lastname@example.org 508-975-4820 Jennifer McNealey email@example.com 917-392-3400